Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 7/20 | 0.31 |
| ▸ | DRD2 | P14416 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25764940 | 0.77 | MEN1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL8404674 | 0.76 | MEN1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL11358535 | 0.74 | PRCP (0.35) | CYP3A4PRCPHTR1ADRD2 | |
| SCHEMBL6677041 | 0.73 | MEN1 (0.35) | MEN1ALDH1A1KMT2A | |
| SCHEMBL12924913 | 0.71 | MAPT (0.33) | ALDH1A1KMT2ACYP3A4DRD2 | |
| SCHEMBL8132766 | 0.69 | ELANE (0.36) | MEN1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL5580304 | 0.65 | HTR1A (0.44) | PRCPHTR1ADRD2 | |
| SCHEMBL2594870 | 0.65 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL8799867 | 0.64 | CHRNB2 (0.37) | PRCPHTR1ADRD2 | |
| SCHEMBL7174440 | 0.63 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009617-A1 | Ruthenium Catalysts and Uses Thereof | CHE CHI-MING | 2011-01-13 | — | — | US | disclosed |
| US-20110009617-A1 | Ruthenium Catalysts and Uses Thereof | CHE CHI-MING | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009617-A1 | Ruthenium Catalysts and Uses Thereof | CYCS, POR, CPNE4 | MEN1 4753/4885ALDH1A1 4465/4885KMT2A 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.